News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
26,559 Results
Type
Article (4057)
Company Profile (5)
Press Release (22496)
Multimedia
Podcasts (39)
Webinars (4)
Section
Business (9893)
Career Advice (39)
Deals (1278)
Drug Delivery (30)
Drug Development (4526)
Employer Resources (12)
FDA (749)
Job Trends (1087)
News (15085)
Policy (1564)
Tag
2027 BioCapital Standard (2)
Academia (81)
Accelerated approval (3)
Adcomms (2)
Allergies (2)
Alliances (2274)
ALS (3)
Alzheimer's disease (44)
Antibody-drug conjugate (ADC) (133)
Approvals (767)
Artificial intelligence (38)
ASCO (66)
Autoimmune disease (17)
Automation (2)
Bankruptcy (9)
Best Places to Work (845)
BIO (1)
Biologics (2)
BIOSECURE Act (7)
Biosimilars (16)
BioSpace Insights (7)
Biotechnology (1)
Bispecific (1)
Bladder cancer (28)
Brain cancer (11)
Breast cancer (90)
Cancer (685)
Cardiovascular disease (49)
Career advice (48)
Career pathing (2)
CAR-T (15)
CDC (14)
CDMO (23)
Cell therapy (30)
Cervical cancer (8)
Clinical research (3907)
Collaboration (117)
Commercialization (6)
Company closure (4)
Compensation (7)
Complete response letters (8)
COVID-19 (209)
CRISPR (3)
CRO (1)
C-suite (135)
Cystic fibrosis (3)
Data (332)
Depression (4)
Dermatology (4)
Diabetes (13)
Diagnostics (99)
Digital health (3)
Diversity, equity & inclusion (3)
Drug discovery (21)
Drug pricing (51)
Drug shortages (1)
Duchenne muscular dystrophy (8)
Earnings (2377)
Editorial (11)
Employer branding (6)
Employer resources (12)
ESMO (53)
Events (2631)
Executive appointments (113)
Eye disease (2)
FDA (896)
Funding (80)
Gene editing (11)
Generative AI (4)
Gene therapy (18)
GLP-1 (89)
Government (340)
Grass and pollen (1)
Guidances (8)
Healthcare (488)
Hematology (9)
HIV (22)
Huntington's disease (2)
IgA nephropathy (3)
Immunology and inflammation (43)
Immuno-oncology (28)
Indications (22)
Infectious disease (244)
Inflammatory bowel disease (12)
Inflation Reduction Act (4)
Influenza (1)
Intellectual property (8)
Interviews (2)
IPO (379)
IRA (12)
Job creations (284)
Job search strategy (40)
JPM (9)
Kidney cancer (6)
Kidney disease (1)
Labor market (15)
Layoffs (72)
Leadership (5)
Legal (403)
Licensing (5)
Liver cancer (8)
Longevity (1)
Lung cancer (156)
Lung diease (2)
Lymphoma (17)
Machine learning (2)
Management (4)
Manufacturing (72)
Marketing (1)
MASH (9)
Medical device (83)
Medtech (84)
Melanoma (33)
Mergers & acquisitions (947)
Metabolic disorders (67)
mRNA (51)
Multiple sclerosis (14)
Neurodegenerative disease (23)
Neuropsychiatric disorders (10)
Neuroscience (97)
NextGen: Class of 2026 (200)
Non-profit (92)
Now hiring (5)
Obesity (44)
Opinion (38)
Ovarian cancer (31)
Pain (7)
Pancreatic cancer (13)
Parkinson's disease (7)
Patents (30)
Patient advocacy (1)
Patient recruitment (15)
Patient selection (2)
People (4075)
Peptides (4)
Pharmaceutical (2)
Pharmacy benefit managers (3)
Phase 1 (1109)
Phase 2 (1734)
Phase 3 (1646)
Pipeline (463)
Policy (66)
Postmarket research (201)
Preclinical (281)
Press Release (2)
Prostate cancer (7)
Psychedelics (11)
Radiopharmaceuticals (21)
Rare diseases (46)
Real estate (213)
Recruiting (4)
Regulatory (1169)
Reports (7)
Research institute (74)
Resumes & cover letters (1)
RNA editing (2)
RSV (19)
Schizophrenia (4)
Series A (18)
Series B (11)
Series C (1)
Sickle cell disease (3)
Special edition (9)
Spinal muscular atrophy (4)
Sponsored (2)
Startups (220)
Stomach cancer (10)
Supply chain (10)
Tariffs (23)
The Weekly (37)
Vaccines (187)
Venture capital (21)
Weight loss (37)
Women's health (6)
Worklife (2)
Date
Today (6)
Last 7 days (32)
Last 30 days (150)
Last 365 days (1044)
2026 (942)
2025 (1024)
2024 (1236)
2023 (1319)
2022 (2974)
2021 (2787)
2020 (2290)
2019 (1546)
2018 (1196)
2017 (1348)
2016 (1159)
2015 (1326)
2014 (867)
2013 (725)
2012 (785)
2011 (880)
2010 (816)
Location
Africa (65)
Alabama (4)
Alaska (1)
Arizona (3)
Asia (1657)
Australia (412)
California (323)
Canada (113)
China (151)
Colorado (7)
Connecticut (9)
Delaware (18)
Europe (4463)
Florida (81)
Georgia (3)
Illinois (17)
India (4)
Indiana (4)
Japan (79)
Kansas (1)
Kentucky (1)
Maryland (77)
Massachusetts (347)
Michigan (2)
Minnesota (8)
Mississippi (1)
Missouri (4)
Montana (1)
Nevada (3)
New Hampshire (5)
New Jersey (382)
New York (101)
North Carolina (30)
Northern California (178)
Ohio (4)
Oregon (1)
Pennsylvania (40)
Rhode Island (4)
South America (61)
South Carolina (1)
Southern California (113)
Tennessee (2)
Texas (36)
United States (1488)
Utah (11)
Virginia (10)
Washington D.C. (5)
Washington State (37)
West Virginia (1)
Wisconsin (4)
26,559 Results for "merck kgaa".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Manufacturing
Lonza agrees to buy 5 Merck KGaA facilities to accelerate US expansion
The Swiss contract development and manufacturing organization will more than double its U.S. footprint by acquiring the Merck KGaA plants.
November 3, 2026
·
2 min read
·
Nick Paul Taylor
M&A
Merck KGaA inks $11B Bio-Techne buyout to expand into cell therapy production
The company is “especially excited” about an immune cell therapy manufacturing technology included in the deal, a Merck KGaA executive said.
June 26, 2026
·
2 min read
·
Nick Paul Taylor
Press Releases
Rapid Micro Biosystems Signs Definitive Agreement to be Acquired by Merck KGaA, Darmstadt, Germany
November 16, 2026
·
7 min read
Mergers & acquisitions
Merck KGaA makes noise in hematology with $1.1B Silence buy
Silence Therapeutics’ lead siRNA asset for the rare blood cancer polycythemia vera has been earning analyst raves in a tight race to challenge Takeda in a potential $2 billion market.
October 19, 2026
·
3 min read
·
Annalee Armstrong
Press Releases
Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany
September 23, 2026
·
6 min read
Press Releases
Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany
October 19, 2026
·
13 min read
Press Releases
Merck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics, Strengthening Rare Disease Pipeline with Innovative siRNA Asset
October 19, 2026
·
7 min read
Press Releases
PIMJETMI® (pimicotinib) Developed by Abbisko Therapeutics and Licensed by Merck KGaA, Darmstadt, Germany Receive U.S. FDA Approval for TGCT
November 11, 2026
·
6 min read
Press Releases
Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab
October 15, 2026
·
6 min read
Press Releases
Evinova Launches Strategic Partnership with Merck KGaA, Darmstadt, Germany to Define the Future of Clinical Development
July 29, 2026
·
3 min read
1 of 2,656
Next